Is SABS or AKTS more profitable?

Aktis Oncology's return on equity of 0.00% beat SAB Biotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets SAB Biotherapeutics N/A -6.74% -6.06% Aktis Oncology N/A N/A N/A

Does the media favor SABS or AKTS?

In the previous week, Aktis Oncology had 2 more articles in the media than SAB Biotherapeutics. MarketBeat recorded 4 mentions for Aktis Oncology and 2 mentions for SAB Biotherapeutics. Aktis Oncology's average media sentiment score of 0.56 beat SAB Biotherapeutics' score of 0.00 indicating that Aktis Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SAB Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aktis Oncology 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to MGTX or SABS?

In the previous week, MeiraGTx had 1 more articles in the media than SAB Biotherapeutics. MarketBeat recorded 3 mentions for MeiraGTx and 2 mentions for SAB Biotherapeutics. MeiraGTx's average media sentiment score of 0.12 beat SAB Biotherapeutics' score of 0.00 indicating that MeiraGTx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MeiraGTx 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SAB Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is REPL or SABS more profitable?

SAB Biotherapeutics' return on equity of -6.74% beat Replimune Group's return on equity. Company Net Margins Return on Equity Return on Assets Replimune Group N/A -159.32% -90.84% SAB Biotherapeutics N/A -6.74% -6.06%

Does the media prefer REPL or SABS?

In the previous week, Replimune Group had 7 more articles in the media than SAB Biotherapeutics. MarketBeat recorded 9 mentions for Replimune Group and 2 mentions for SAB Biotherapeutics. Replimune Group's average media sentiment score of 0.24 beat SAB Biotherapeutics' score of 0.00 indicating that Replimune Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Replimune Group 1 Very Positive mention(s) 0 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SAB Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor SABS or MNKD?

In the previous week, MannKind had 1 more articles in the media than SAB Biotherapeutics. MarketBeat recorded 3 mentions for MannKind and 2 mentions for SAB Biotherapeutics. MannKind's average media sentiment score of 0.72 beat SAB Biotherapeutics' score of 0.00 indicating that MannKind is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SAB Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MannKind 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor SABS or ALMS?

In the previous week, Alumis had 2 more articles in the media than SAB Biotherapeutics. MarketBeat recorded 4 mentions for Alumis and 2 mentions for SAB Biotherapeutics. Alumis' average media sentiment score of 0.57 beat SAB Biotherapeutics' score of 0.00 indicating that Alumis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SAB Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Alumis 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

SAB Biotherapeutics (SABS) Competitors

$3.39 -0.11 (-3.14%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$3.37 -0.02 (-0.62%)

As of 09/23/2026 07:30 PM Eastern

Compare

SABS vs. AKTS, MGTX, REPL, MNKD, and ALMS

Should you buy SAB Biotherapeutics stock or one of its competitors? SAB Biotherapeutics's main competitors and comparable companies include Aktis Oncology (AKTS), MeiraGTx (MGTX), Replimune Group (REPL), MannKind (MNKD), and Alumis (ALMS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does SAB Biotherapeutics compare to Aktis Oncology?

SAB Biotherapeutics (NASDAQ:SABS) and Aktis Oncology (NASDAQ:AKTS) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk.

In the previous week, Aktis Oncology had 2 more articles in the media than SAB Biotherapeutics. MarketBeat recorded 4 mentions for Aktis Oncology and 2 mentions for SAB Biotherapeutics. Aktis Oncology's average media sentiment score of 0.56 beat SAB Biotherapeutics' score of 0.00 indicating that Aktis Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SAB Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aktis Oncology	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aktis Oncology's return on equity of 0.00% beat SAB Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SAB Biotherapeutics	N/A	-6.74%	-6.06%
Aktis Oncology	N/A	N/A	N/A

SAB Biotherapeutics has higher earnings, but lower revenue than Aktis Oncology. Aktis Oncology is trading at a lower price-to-earnings ratio than SAB Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SAB Biotherapeutics	$1.32M	233.68	$13.27M	-$1.30	N/A
Aktis Oncology	$6.50M	163.07	-$63.73M	-$0.82	N/A

SAB Biotherapeutics currently has a consensus target price of $12.00, suggesting a potential upside of 253.98%. Aktis Oncology has a consensus target price of $35.63, suggesting a potential upside of 80.65%. Given SAB Biotherapeutics' higher probable upside, research analysts plainly believe SAB Biotherapeutics is more favorable than Aktis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SAB Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91

7.8% of SAB Biotherapeutics shares are held by institutional investors. Comparatively, 28.8% of Aktis Oncology shares are held by institutional investors. 7.4% of SAB Biotherapeutics shares are held by insiders. Comparatively, 3.3% of Aktis Oncology shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Aktis Oncology beats SAB Biotherapeutics on 9 of the 14 factors compared between the two stocks.

How does SAB Biotherapeutics compare to MeiraGTx?

MeiraGTx (NASDAQ:MGTX) and SAB Biotherapeutics (NASDAQ:SABS) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.

SAB Biotherapeutics has lower revenue, but higher earnings than MeiraGTx. SAB Biotherapeutics is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MeiraGTx	$397.50M	2.84	-$114.20M	$0.71	16.55
SAB Biotherapeutics	$1.32M	233.68	$13.27M	-$1.30	N/A

MeiraGTx presently has a consensus target price of $26.17, indicating a potential upside of 122.70%. SAB Biotherapeutics has a consensus target price of $12.00, indicating a potential upside of 253.98%. Given SAB Biotherapeutics' higher probable upside, analysts clearly believe SAB Biotherapeutics is more favorable than MeiraGTx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MeiraGTx	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.88
SAB Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

MeiraGTx has a beta of 1.27, indicating that its stock price is 27% more volatile than the broader market. Comparatively, SAB Biotherapeutics has a beta of 0.53, indicating that its stock price is 47% less volatile than the broader market.

67.5% of MeiraGTx shares are owned by institutional investors. Comparatively, 7.8% of SAB Biotherapeutics shares are owned by institutional investors. 7.4% of MeiraGTx shares are owned by insiders. Comparatively, 7.4% of SAB Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, MeiraGTx had 1 more articles in the media than SAB Biotherapeutics. MarketBeat recorded 3 mentions for MeiraGTx and 2 mentions for SAB Biotherapeutics. MeiraGTx's average media sentiment score of 0.12 beat SAB Biotherapeutics' score of 0.00 indicating that MeiraGTx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MeiraGTx	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
SAB Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MeiraGTx has a net margin of 19.87% compared to SAB Biotherapeutics' net margin of 0.00%. MeiraGTx's return on equity of 283.85% beat SAB Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MeiraGTx	19.87%	283.85%	29.39%
SAB Biotherapeutics	N/A	-6.74%	-6.06%

Summary

MeiraGTx beats SAB Biotherapeutics on 13 of the 17 factors compared between the two stocks.

How does SAB Biotherapeutics compare to Replimune Group?

Replimune Group (NASDAQ:REPL) and SAB Biotherapeutics (NASDAQ:SABS) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

SAB Biotherapeutics has higher revenue and earnings than Replimune Group. Replimune Group is trading at a lower price-to-earnings ratio than SAB Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Replimune Group	N/A	N/A	-$313.94M	-$3.15	N/A
SAB Biotherapeutics	$1.32M	233.68	$13.27M	-$1.30	N/A

92.5% of Replimune Group shares are owned by institutional investors. Comparatively, 7.8% of SAB Biotherapeutics shares are owned by institutional investors. 5.4% of Replimune Group shares are owned by company insiders. Comparatively, 7.4% of SAB Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Replimune Group had 7 more articles in the media than SAB Biotherapeutics. MarketBeat recorded 9 mentions for Replimune Group and 2 mentions for SAB Biotherapeutics. Replimune Group's average media sentiment score of 0.24 beat SAB Biotherapeutics' score of 0.00 indicating that Replimune Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Replimune Group	1 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
SAB Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Replimune Group has a beta of 0.94, indicating that its stock price is 6% less volatile than the broader market. Comparatively, SAB Biotherapeutics has a beta of 0.53, indicating that its stock price is 47% less volatile than the broader market.

SAB Biotherapeutics' return on equity of -6.74% beat Replimune Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Replimune Group	N/A	-159.32%	-90.84%
SAB Biotherapeutics	N/A	-6.74%	-6.06%

Replimune Group currently has a consensus price target of $12.00, indicating a potential downside of 7.41%. SAB Biotherapeutics has a consensus price target of $12.00, indicating a potential upside of 253.98%. Given SAB Biotherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe SAB Biotherapeutics is more favorable than Replimune Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Replimune Group	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.60
SAB Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

Summary

SAB Biotherapeutics beats Replimune Group on 10 of the 15 factors compared between the two stocks.

How does SAB Biotherapeutics compare to MannKind?

SAB Biotherapeutics (NASDAQ:SABS) and MannKind (NASDAQ:MNKD) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, valuation, dividends, profitability and analyst recommendations.

7.8% of SAB Biotherapeutics shares are owned by institutional investors. Comparatively, 49.6% of MannKind shares are owned by institutional investors. 7.4% of SAB Biotherapeutics shares are owned by insiders. Comparatively, 2.6% of MannKind shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

SAB Biotherapeutics has higher earnings, but lower revenue than MannKind. MannKind is trading at a lower price-to-earnings ratio than SAB Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SAB Biotherapeutics	$1.32M	233.68	$13.27M	-$1.30	N/A
MannKind	$348.97M	3.08	$5.86M	-$0.13	N/A

In the previous week, MannKind had 1 more articles in the media than SAB Biotherapeutics. MarketBeat recorded 3 mentions for MannKind and 2 mentions for SAB Biotherapeutics. MannKind's average media sentiment score of 0.72 beat SAB Biotherapeutics' score of 0.00 indicating that MannKind is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SAB Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MannKind	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

SAB Biotherapeutics has a beta of 0.53, meaning that its stock price is 47% less volatile than the broader market. Comparatively, MannKind has a beta of 1.1, meaning that its stock price is 10% more volatile than the broader market.

SAB Biotherapeutics presently has a consensus price target of $12.00, indicating a potential upside of 253.98%. MannKind has a consensus price target of $8.34, indicating a potential upside of 149.81%. Given SAB Biotherapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe SAB Biotherapeutics is more favorable than MannKind.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SAB Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
MannKind	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50

SAB Biotherapeutics has a net margin of 0.00% compared to MannKind's net margin of -11.08%. SAB Biotherapeutics' return on equity of -6.74% beat MannKind's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SAB Biotherapeutics	N/A	-6.74%	-6.06%
MannKind	-11.08%	-11.21%	-6.31%

Summary

SAB Biotherapeutics beats MannKind on 10 of the 16 factors compared between the two stocks.

How does SAB Biotherapeutics compare to Alumis?

SAB Biotherapeutics (NASDAQ:SABS) and Alumis (NASDAQ:ALMS) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, risk, valuation and profitability.

SAB Biotherapeutics has higher earnings, but lower revenue than Alumis. SAB Biotherapeutics is trading at a lower price-to-earnings ratio than Alumis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SAB Biotherapeutics	$1.32M	233.68	$13.27M	-$1.30	N/A
Alumis	$24.05M	40.04	-$243.32M	-$3.86	N/A

SAB Biotherapeutics has a net margin of 0.00% compared to Alumis' net margin of -5,933.46%. SAB Biotherapeutics' return on equity of -6.74% beat Alumis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SAB Biotherapeutics	N/A	-6.74%	-6.06%
Alumis	-5,933.46%	-93.15%	-74.50%

SAB Biotherapeutics currently has a consensus target price of $12.00, suggesting a potential upside of 253.98%. Alumis has a consensus target price of $33.27, suggesting a potential upside of 347.21%. Given Alumis' stronger consensus rating and higher probable upside, analysts plainly believe Alumis is more favorable than SAB Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SAB Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Alumis	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85

7.8% of SAB Biotherapeutics shares are owned by institutional investors. 7.4% of SAB Biotherapeutics shares are owned by company insiders. Comparatively, 33.7% of Alumis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

SAB Biotherapeutics has a beta of 0.53, suggesting that its share price is 47% less volatile than the broader market. Comparatively, Alumis has a beta of -0.81, suggesting that its share price is 181% less volatile than the broader market.

In the previous week, Alumis had 2 more articles in the media than SAB Biotherapeutics. MarketBeat recorded 4 mentions for Alumis and 2 mentions for SAB Biotherapeutics. Alumis' average media sentiment score of 0.57 beat SAB Biotherapeutics' score of 0.00 indicating that Alumis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SAB Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alumis	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Alumis beats SAB Biotherapeutics on 9 of the 17 factors compared between the two stocks.

Get SAB Biotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SABS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SABS vs. The Competition

Export

Metric	SAB Biotherapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$318.45M	$3.98B	$7.31B	$13.29B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	-2.61	13.88	274.02	25.69
Price / Sales	233.68	1,311.42	632.76	76.07
Price / Cash	10.24	113.29	77.80	52.76
Price / Book	1.07	15.30	10.44	6.32
Net Income	$13.27M	-$22.82M	$3.49B	$359.73M
7 Day Performance	-3.14%	-1.71%	-0.66%	0.17%
1 Month Performance	-6.35%	-6.17%	-3.16%	-3.27%
1 Year Performance	56.94%	30.64%	15.15%	5.58%

SAB Biotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SABS SAB Biotherapeutics	1.9991 of 5 stars	$3.39 -3.1%	$12.00 +254.0%	+50.0%	$318.45M	$1.32M	N/A	86
AKTS Aktis Oncology	2.9972 of 5 stars	$22.41 -3.3%	$35.63 +59.0%	N/A	$1.25B	$6.50M	N/A	79
MGTX MeiraGTx	3.7097 of 5 stars	$12.76 -0.9%	$26.17 +105.1%	+44.2%	$1.24B	$81.39M	17.97	393	News Coverage Positive News Analyst Upgrade
REPL Replimune Group	1.6964 of 5 stars	$13.03 -0.6%	$12.00 -7.9%	+199.3%	$1.23B	N/A	N/A	465
MNKD MannKind	3.0228 of 5 stars	$3.56 -5.1%	$8.34 +134.4%	-37.6%	$1.21B	$348.97M	N/A	592

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SABS) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

SAB Biotherapeutics (SABS) Competitors

SABS vs. AKTS, MGTX, REPL, MNKD, and ALMS

How does SAB Biotherapeutics compare to Aktis Oncology?

Summary

How does SAB Biotherapeutics compare to MeiraGTx?

Summary

How does SAB Biotherapeutics compare to Replimune Group?

Summary

How does SAB Biotherapeutics compare to MannKind?

Summary

How does SAB Biotherapeutics compare to Alumis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SABS vs. The Competition

SAB Biotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

SAB Biotherapeutics (SABS) Competitors

SABS vs. AKTS, MGTX, REPL, MNKD, and ALMS

How does SAB Biotherapeutics compare to Aktis Oncology?

Does the media favor SABS or AKTS?

Is SABS or AKTS more profitable?

Which has preferable valuation and earnings, SABS or AKTS?

Do analysts rate SABS or AKTS?

Do insiders & institutionals have more ownership in SABS or AKTS?

Summary

How does SAB Biotherapeutics compare to MeiraGTx?

Which has stronger valuation and earnings, MGTX or SABS?

Do analysts rate MGTX or SABS?

Which has more risk & volatility, MGTX or SABS?

Do institutionals & insiders believe in MGTX or SABS?

Does the media refer more to MGTX or SABS?

Is MGTX or SABS more profitable?

Summary

How does SAB Biotherapeutics compare to Replimune Group?

Which has better earnings & valuation, REPL or SABS?

Do insiders & institutionals believe in REPL or SABS?

Does the media prefer REPL or SABS?

Which has more volatility & risk, REPL or SABS?

Is REPL or SABS more profitable?

Do analysts recommend REPL or SABS?

Summary

How does SAB Biotherapeutics compare to MannKind?

Do institutionals & insiders believe in SABS or MNKD?

Which has better valuation and earnings, SABS or MNKD?

Does the media favor SABS or MNKD?

Which has more volatility and risk, SABS or MNKD?

Do analysts recommend SABS or MNKD?

Is SABS or MNKD more profitable?

Summary

How does SAB Biotherapeutics compare to Alumis?

Which has higher valuation and earnings, SABS or ALMS?

Is SABS or ALMS more profitable?

Do analysts recommend SABS or ALMS?

Do institutionals & insiders have more ownership in SABS or ALMS?

Which has more volatility and risk, SABS or ALMS?

Does the media favor SABS or ALMS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SABS vs. The Competition

SAB Biotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools